Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ
Market Cap
$5.87B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
3 of 809
Rank in Industry
3 of 445
Largest Insider Buys in Sector
MDGL Stock Price History Chart
MDGL Stock Performance
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Insider Activity of Madrigal Pharmaceuticals, Inc.
Over the last 12 months, insiders at Madrigal Pharmaceuticals, Inc. have bought $77.75M and sold $82.64M worth of Madrigal Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Madrigal Pharmaceuticals, Inc. have bought $77.75M and sold $91.38M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP (director) — $1.17B.
The last purchase of 20,633 shares for transaction amount of $4.71M was made by BAKER BROS. ADVISORS LP (director) on 2023‑12‑14.
List of Insider Buy and Sell Transactions, Madrigal Pharmaceuticals, Inc.
| 2024-06-14 | Sale | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 1,900 0.0085% | $280.00 | $532,000 | -0.01% | |
| 2024-06-12 | Sale | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2,000 0.0092% | $285.00 | $570,000 | -2.98% | |
| 2024-05-21 | Sale | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 1,036 0.0046% | $231.34 | $239,668 | +1.24% | |
| 2024-05-14 | Sale | CRAVES FRED B | director | 22,489 0.1065% | $212.88 | $4.79M | +15.56% | |
| 2024-04-08 | Sale | Taub Rebecca | Pres., R&D, and CMO | 2,676 0.0126% | $245.99 | $658,258 | -6.74% | |
| 2024-04-08 | Sale | FRIEDMAN PAUL A | director | 26,270 0.1239% | $246.19 | $6.47M | -6.74% | |
| 2024-04-05 | Sale | Taub Rebecca | Pres., R&D, and CMO | 22,228 0.1058% | $242.84 | $5.4M | -4.39% | |
| 2024-04-05 | Sale | Taub Rebecca | Pres., R&D, and CMO | 27,506 0.1312% | $243.36 | $6.69M | -4.39% | |
| 2024-04-05 | Sale | FRIEDMAN PAUL A | director | 27,613 0.1317% | $243.40 | $6.72M | -4.39% | |
| 2024-04-04 | Sale | Taub Rebecca | Pres., R&D, and CMO | 13,339 0.0636% | $241.81 | $3.23M | -3.64% | |
| 2024-04-04 | Sale | Taub Rebecca | Pres., R&D, and CMO | 18,537 0.0888% | $242.91 | $4.5M | -3.64% | |
| 2024-04-04 | Sale | FRIEDMAN PAUL A | director | 18,710 0.0897% | $242.96 | $4.55M | -3.64% | |
| 2024-04-03 | Sale | Taub Rebecca | Pres., R&D, and CMO | 6,839 0.0342% | $244.24 | $1.67M | -4.99% | |
| 2024-04-03 | Sale | Taub Rebecca | Pres., R&D, and CMO | 27,845 0.1399% | $245.14 | $6.83M | -4.99% | |
| 2024-04-03 | Sale | FRIEDMAN PAUL A | director | 27,407 0.1377% | $245.12 | $6.72M | -4.99% | |
| 2024-04-02 | Sale | Daly James M | director | 10,912 0.0548% | $244.51 | $2.67M | -4.26% | |
| 2024-04-02 | Sale | BATE KENNETH | director | 11,212 0.0563% | $244.49 | $2.74M | -4.26% | |
| 2024-04-01 | Sale | Levy Richard S | director | 11,000 0.0557% | $257.49 | $2.83M | -8.05% | |
| 2024-04-01 | Sale | Daly James M | director | 21,577 0.1091% | $257.24 | $5.55M | -8.05% | |
| 2024-04-01 | Sale | BATE KENNETH | director | 21,277 0.1076% | $257.26 | $5.47M | -8.05% |
Insider Historical Profitability
39.49%
| BAKER BROS. ADVISORS LP | director | 1793403 9.0839% | $275.36 | 9 | 0 | |
| Taub Rebecca | Chief Medical Officer, EVP R&D | 458999 3.3204% | $275.36 | 0 | 8 | |
| FRIEDMAN PAUL A | Chief Executive Officer | 185735 0.8161% | $275.36 | 2 | 5 | <0.0001% |
| CRAVES FRED B | 413362 0.2172% | $275.36 | 1 | 6 | <0.0001% | |
| Lynch Brian Joseph | SVP and General Counsel | 15001 0.076% | $275.36 | 0 | 6 | |
| Levy Richard S | director | 10298 0.0461% | $275.36 | 3 | 2 | +602.61% |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 5500 0.0287% | $275.36 | 0 | 9 | |
| BATE KENNETH | director | 1198 0.0057% | $275.36 | 0 | 2 | |
| Daly James M | director | 1198 0.0057% | $275.36 | 0 | 2 | |
| Bahcall Safi R | President and CEO | 2053135 10.3995% | $275.36 | 12 | 0 | +16.52% |
| Gollust Keith R | director | 1539169 7.7962% | $275.36 | 13 | 7 | +9.47% |
| WILSON ROBERT N | director | 754118 3.8198% | $275.36 | 5 | 0 | <0.0001% |
| Chen Lan Bo | 620035 3.1406% | $275.36 | 1 | 0 | +32.54% | |
| Chen Lin Huey | 10 percent owner | 620035 3.1406% | $275.36 | 1 | 0 | +32.54% |
| Kovner Bruce | 340970 1.7271% | $275.36 | 51 | 21 | +19.69% | |
| BAY CITY CAPITAL LLC | 10 percent owner | 42875 0.2172% | $275.36 | 0 | 5 | |
| Schneebaum Marc R | Chief Financial Officer | 41668 0.2111% | $275.36 | 0 | 1 | |
| REARDON WILLIAM S | director | 36561 0.1852% | $275.36 | 1 | 0 | +11.11% |
| Vukovic Vojo | SVP, Chief Medical Officer | 35249 0.1785% | $275.36 | 6 | 2 | +36.93% |
| BAILEY MICHAEL P | Sr. VP, Chief Comm. Officer | 29627 0.1501% | $275.36 | 0 | 1 | |
| Jacobson Eric W | Sr. VP, Research and CMO | 25300 0.1281% | $275.36 | 1 | 0 | |
| Rieder Wendy E | VP, IP and Legal, Gen. Counsel | 19823 0.1004% | $275.36 | 0 | 4 | |
| Ehrlich Keith S | VP, Fin. and Admin., CFO | 17573 0.089% | $275.36 | 0 | 3 | |
| Chadwick Jeremy G | Sr. VP, Pgm Mgmt and Clin Ops | 15853 0.0803% | $275.36 | 0 | 1 | |
| Singh Amar | Sr. VP, Chief Business Officer | 15161 0.0768% | $275.36 | 0 | 1 | |
| Koya Keizo | Sr. VP, Drug Development | 12999 0.0658% | $275.36 | 1 | 4 | +26.49% |
| Williams Martin D | Sr. VP, Business Dev., CBO | 200 0.001% | $275.36 | 1 | 0 | |
| Sukhija Remy | Chief Commercial Officer | 0 0% | $275.36 | 0 | 1 | |
| MILLIGAN DAVID V | director | 0 0% | $275.36 | 0 | 2 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Janus Henderson | $694.53M | 12.21 | 2.6M | -10.36% | -$80.3M | 0.38 | |
| Baker Bros Advisors LP | $526.01M | 9.24 | 1.97M | 0% | +$0 | 6.61 | |
| Avoro Capital Advisors Llc | $519.24M | 9.12 | 1.94M | +2.94% | +$14.84M | 6.22 | |
| Paulson & Co. | $474M | 8.33 | 1.77M | +60.53% | +$178.72M | 32.75 | |
| The Vanguard Group | $445.64M | 7.83 | 1.67M | +5.97% | +$25.12M | 0.01 | |
| BlackRock | $323.22M | 5.68 | 1.21M | -0.18% | -$579,743.84 | 0.01 | |
| T. Rowe Price | $214.49M | 3.77 | 803,213 | +106.63% | +$110.68M | 0.03 | |
| Fidelity Investments | $190.64M | 3.35 | 713,914 | +14.2% | +$23.7M | 0.01 | |
| State Street | $166.88M | 2.93 | 624,938 | -10.82% | -$20.24M | 0.01 | |
| Perceptive Advisors | $114.81M | 2.02 | 429,953 | +184.45% | +$74.45M | 0.07 | |
| Artisan Partners | $107.27M | 1.89 | 401,709 | +35.49% | +$28.1M | 0.16 | |
| RTW Investments, LP | $106.03M | 1.86 | 397,047 | -51.29% | -$111.66M | 1.57 | |
| Geode Capital Management | $92.64M | 1.63 | 346,857 | +3.15% | +$2.83M | 0.01 | |
| Morgan Stanley | $77.07M | 1.35 | 288,606 | +89.97% | +$36.5M | 0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $76.36M | 1.34 | 285,931 | +44.29% | +$23.44M | 1.95 | |
| RA Capital Management, L.P. | $54.61M | 0.96 | 204,500 | 0% | +$0 | 0.06 | |
| Bain Capital Life Sciences Investors Llc | $52.61M | 0.92 | 196,995 | -39.31% | -$34.08M | 5.28 | |
| Armistice Capital Llc | $44.86M | 0.79 | 168,000 | +236% | +$31.51M | 0.54 | |
| Tcg Crossover Management Llc | $39.86M | 0.7 | 149,283 | -17.03% | -$8.18M | 0.06 | |
| Northern Trust | $35.08M | 0.62 | 131,358 | -2.48% | -$894,049.91 | 0.01 | |
| Tao Capital Management Lp | $34.86M | 0.61 | 130,529 | 0% | +$0 | 33.03 | |
| UBS | $33.49M | 0.59 | 125,415 | +41.91% | +$9.89M | 0.01 | |
| Polar Capital | $33.43M | 0.59 | 125,205 | New | +$33.43M | 0.19 | |
| Charles Schwab | $32.76M | 0.58 | 122,692 | +2.06% | +$662,259.21 | 0.01 | |
| Affinity Asset Advisors | $30.71M | 0.54 | 115,000 | +15% | +$4.01M | 5.45 | |
| Bank of America | $30.21M | 0.53 | 113,114 | -1.56% | -$478,001.59 | <0.01 | |
| Artal Group S A | $29.51M | 0.52 | 110,507 | New | +$29.51M | 0.16 | |
| Rheos Capital Works Inc | $29.43M | 0.52 | 110,215 | New | +$29.43M | 1.41 | |
| AlpInvest Partners | $28.24M | 0.5 | 105,744 | -50% | -$28.24M | 11.03 | |
| Emerald Advisers, Inc. | $27.14M | 0.48 | 101,623 | +112.95% | +$14.39M | 1.1 | |
| American Century Investments | $26.1M | 0.46 | 97,752 | +28.84% | +$5.84M | 0.02 | |
| Lord Abbett | $25.93M | 0.46 | 97,103 | New | +$25.93M | 0.09 | |
| Point72 Asset Management | $24.99M | 0.44 | 93,571 | New | +$24.99M | 0.05 | |
| Connor Clark & Lunn Investment Management Ltd | $24.99M | 0.44 | 93,597 | +72.98% | +$10.55M | 0.06 | |
| Ensign Peak Advisors Inc | $24.63M | 0.43 | 92,218 | +50.16% | +$8.23M | 0.04 | |
| Mirae Asset Global Investments Co Ltd | $24.48M | 0.43 | 92,253 | +49.98% | +$8.16M | 0.02 | |
| Goldman Sachs | $24.51M | 0.43 | 91,789 | +7.86% | +$1.79M | 0.01 | |
| Invesco | $21.41M | 0.38 | 80,192 | +825.79% | +$19.1M | 0.01 | |
| EMERALD MUTUAL FUND ADVISERS TRUST | $20.23M | 0.36 | 75,759 | +92.87% | +$9.74M | 1.07 | |
| Ecor1 Capital Llc | $20.03M | 0.35 | 75,000 | New | +$20.03M | 0.51 | |
| Nuveen | $18.88M | 0.33 | 70,712 | +18.11% | +$2.89M | 0.01 | |
| Alger | $17.24M | 0.3 | 64,576 | +256.83% | +$12.41M | 0.09 | |
| Bioimpact Capital Llc | $16.4M | 0.29 | 61,399 | +50.08% | +$5.47M | 2.65 | |
| Macquarie Group | $15.74M | 0.28 | 58,957 | +106.87% | +$8.13M | 0.01 | |
| BNY Mellon | $15.46M | 0.27 | 57,883 | -6.91% | -$1.15M | <0.01 | |
| JPMorgan Chase | $14.8M | 0.26 | 55,404 | -6.59% | -$1.04M | <0.01 | |
| Tri Locum Partners Lp | $14.25M | 0.25 | 53,355 | +109.04% | +$7.43M | 5.03 | |
| Sio Capital Management LLC | $13.62M | 0.24 | 51,000 | New | +$13.62M | 4.82 | |
| Driehaus Capital Management LLC | $13.54M | 0.24 | 50,709 | New | +$13.54M | 0.14 | |
| Td Asset Management Inc | $13.44M | 0.24 | 50,330 | +223.87% | +$9.29M | 0.01 |